Cargando…

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiujuan, Tang, Peng, Li, Shifei, Wang, Shushu, Liang, Yueyang, Zhong, Ling, Ren, Lin, Zhang, Ting, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827032/ https://www.ncbi.nlm.nih.gov/pubmed/29483583 http://dx.doi.org/10.1038/s41467-018-03210-2

Ejemplares similares

Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial
por: Yan, Wenting, et al.
Publicado: (2022)

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
por: Yan, Min, et al.
Publicado: (2022)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

Sphk1 promotes breast epithelial cell proliferation via NF-κB-p65-mediated cyclin D1 expression
por: Li, Shifei, et al.
Publicado: (2016)

Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial
por: Ke, Liang-Ru, et al.
Publicado: (2017)

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer
por: Gu, Liyan, et al.
Publicado: (2019)

Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer
por: Wu, Yuan, et al.
Publicado: (2019)

Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles
por: Zhong, Yuxin, et al.
Publicado: (2020)

The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer
por: Zhou, Ning-ning, et al.
Publicado: (2018)

Lobaplatin: Multiple toxicities: case report.
Publicado: (2020)

A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients
por: Yuan, Yuan, et al.
Publicado: (2021)

Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer
por: Zhang, Chao, et al.
Publicado: (2022)

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo
por: Zhou, Zijun, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer
por: Wang, Minghao, et al.
Publicado: (2017)

Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study
por: Lu, Haohao, et al.
Publicado: (2023)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
por: Chaft, Jamie E., et al.
Publicado: (2022)

Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study
por: Masui, Toshihiko, et al.
Publicado: (2023)

Lobaplatin Inhibits the Proliferation of Hepatollular Carcinoma Through P53 Apoptosis Axis
por: Wang, Ying, et al.
Publicado: (2012)

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
por: Velenik, Vaneja, et al.
Publicado: (2011)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial()()
por: Wang, Si-Yang, et al.
Publicado: (2018)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
por: Gietema, J. A., et al.
Publicado: (1993)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo
por: Zhang, Hongming, et al.
Publicado: (2016)

Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
por: Wu, Qiong, et al.
Publicado: (2010)

Lobaplatin-Based Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastasis from Appendiceal and Colorectal Cancer: Safety and Efficacy Profiles
por: Pei, Wei, et al.
Publicado: (2020)

The anti-tumor effects of the combination of microwave hyperthermia and lobaplatin against breast cancer cells in vitro and in vivo
por: Li, Xiaohu, et al.
Publicado: (2022)

Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: A retrospective clinical study
por: Zhong, Yuxin, et al.
Publicado: (2023)

Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin
por: Liang, Xuexia, et al.
Publicado: (2022)

Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression
por: Tian, Wuguo, et al.
Publicado: (2018)

A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy
por: PENG, YU, et al.
Publicado: (2015)

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
por: Li, Jian, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway
por: Liang, Yueyang, et al.
Publicado: (2018)

Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
por: Mao, Xiaoyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ccjdhtegm637foo171s3ho5lbu